Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.
Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation.
Andiamo! Moving forward with autologous hematopoietic transplantation for highly active MS
Mouse models for multiple sclerosis: historical facts and future implications.
Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.
Non-invasive neuromodulation to improve gait in chronic multiple sclerosis: a randomized double blind controlled pilot trial.
Rapidly progressive cerebellar ataxia in West Wales.
A regenerative approach to the treatment of multiple sclerosis.
Spinal cord gray matter atrophy correlates with multiple sclerosis disability.
Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica.
Mycophenolate mofetil in multiple sclerosis.
Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo.
Precision medicine in chronic disease management: The MS BioScreen.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study.
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse.
Biogen Idec and Genentech Announce Restructuring of anti-CD20 Collaboration Agreement
CellCept Drug Details
Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.
Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold
Unusual association of Arnold-Chiari malformation and vitamin B12 deficiency.
Safety study of BIIB033 in subjects with multiple sclerosis
LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis.
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients

Pages